作者
Emma Day, Margaret Hellard, Carla Treloar, Julie Bruneau, Natasha K Martin, Anne Øvrehus, Olav Dalgard, Andrew Lloyd, John Dillon, Matt Hickman, Jude Byrne, Alain Litwin, Mojca Maticic, Philip Bruggmann, Havard Midgard, Brianna Norton, Stacey Trooskin, Jeffrey V Lazarus, Jason Grebely, International Network on Hepatitis in Substance Users (INHSU)
发表日期
2019/1
来源
Liver International
卷号
39
期号
1
页码范围
20-30
简介
The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of 39%, representing an estimated 6.1 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow‐up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of …
学术搜索中的文章
E Day, M Hellard, C Treloar, J Bruneau, NK Martin… - Liver International, 2019